Abstract | BACKGROUND: AIM: METHODS: RESULTS: Four patients were intubated in the ED either before or after receiving icatibant; three of these were extubated within 24 h of treatment. Eight patients received early icatibant and did not require intubation. The time from onset of airway angioedema to ED presentation ranged from 1 h to 3 days (median 4 h); from ED presentation to receiving icatibant, from 30 minutes to 3 days (median 3 h); and to onset of symptom improvement after icatibant, 15 minutes to 7 h (median 2 h). One patient received a second dose of icatibant. CONCLUSION: All patients improved after receiving icatibant, consistent with its bradykinin receptor blocking mechanism. Icatibant rapidly reversed symptoms, and appeared to avert the need for intubation or expedite extubation. Timely use of icatibant in ACE inhibitor-associated angioedema may avert the need for invasive airway procedures and intensive care unit admission.
|
Authors | J S Fok, C H Katelaris, A F Brown, W B Smith |
Journal | Internal medicine journal
(Intern Med J)
Vol. 45
Issue 8
Pg. 821-7
(Aug 2015)
ISSN: 1445-5994 [Electronic] Australia |
PMID | 25944565
(Publication Type: Journal Article)
|
Copyright | © 2015 Royal Australasian College of Physicians. |
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Bradykinin B2 Receptor Antagonists
- icatibant
- Bradykinin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angioedema
(chemically induced, drug therapy)
- Angiotensin-Converting Enzyme Inhibitors
(adverse effects)
- Bradykinin
(analogs & derivatives, therapeutic use)
- Bradykinin B2 Receptor Antagonists
(therapeutic use)
- Clinical Decision-Making
(methods)
- Emergency Service, Hospital
(standards)
- Female
- Humans
- Intubation, Intratracheal
- Larynx
(pathology)
- Male
- Middle Aged
- Oropharynx
(pathology)
|